EHS
EHS

Kite collaborates with Gadeta to develop novel gamma delta TCR therapies for various cancers

Kite, a Gilead Company, and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors, have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.
EHS
Back to top button